Exhaled leukotrienes and prostaglandins in asthma

Montuschi, Paolo; Barnes, Peter J.

doi:10.1067/mai.2002.122461

Cited by 206 publications

(197 citation statements)

References 24 publications

Supporting

Mentioning

181

Contrasting

Unclassified

Order By: Relevance

“…There is considerable variability in exhaled pH in COPD patients, which is greater than in normal subjects [555]. There is an increase in the concentration of leukotriene B 4 in COPD patients, which is further increased during exacerbations [551,556,557]. Increases in prostaglandin E 2 and IL-6 have also been reported in COPD patients [556,558].…”

Section: Inflammatory Mediatorsmentioning

confidence: 71%

“…There is an increase in the concentration of leukotriene B 4 in COPD patients, which is further increased during exacerbations [551,556,557]. Increases in prostaglandin E 2 and IL-6 have also been reported in COPD patients [556,558]. It is unclear how most of these biomarkers relate to disease severity and patient-centred outcomes.…”

Section: Inflammatory Mediatorsmentioning

confidence: 97%

See 1 more Smart Citation

Outcomes for COPD pharmacological trials: from lung function to biomarkers

Cazzola¹,

MacNee²,

Martínez³

et al. 2008

European Respiratory Journal

737

566

View full text Add to dashboard Cite

Section: Inflammatory Mediatorsmentioning

confidence: 71%

Section: Inflammatory Mediatorsmentioning

confidence: 97%

Outcomes for COPD pharmacological trials: from lung function to biomarkers

Cazzola¹,

MacNee²,

Martínez³

et al. 2008

European Respiratory Journal

737

566

View full text Add to dashboard Cite

“…Hence, thromboxane synthesis is usually assessed by measuring TxB 2 and EBC TxB 2 has been measured using EIA [ 83 ]. PGE 2 is present in the EBC of healthy subjects, with upper normal limits not exceeding 75 pg/mL [ 36 ], although there is variability regarding normal values [ 83 ].…”

Section: Prostanoids: Prostaglandins Prostacyclin and Throm Boxanesmentioning

confidence: 99%

Exhaled breath condensate: a comprehensive update

Ahmadzai

Huang²,

Hettiarachchi³

et al. 2013

Clinical Chemistry and Laboratory Medicine

View full text Add to dashboard Cite

Since the late 1990s, a surge in interest in the analysis of exhaled breath condensate (EBC) resulted in the American Thoracic Society and European Respiratory Society (ATS/ERS) organising a Task Force in 2001 to develop guidelines on EBC collection and measurement of biomarkers. This Task Force published their guidelines in 2005 based on literature and expert opinions at that time, and multiple shortcomings and knowledge deficits were also identified. The clinical application of EBC collection and its biomarkers are currently still limited by several of these knowledge gaps, hence further guidelines for standardisation are required to ensure external validity. Using related articles produced since the publication of the ATS/ERS Task Force report, this paper attempts to provide a comprehensive update to the original guideline and review the methodological shortcomings identified. This review can hopefully serve as a yardstick for future studies involving this emerging clinical tool.

show abstract

“…Leukotriene B 4 (LTB 4 ) is a chemotactic factor for neutrophils [18], and increased levels of LTB 4 have been found in states of neutrophilic airway inflammation like COPD [19,20]. Cysteinyl leukotrienes (cysLTs) have been associated with eosinophilic inflammation [21], and increased cysLT concentrations in EBC have been found in asthmatic subjects [19,22]. The effect of oxidative stress can be assessed by measuring the EBC level of 8-isoprostane, a marker of lipid peroxidation [23].…”

mentioning

confidence: 99%

Bronchial nitric oxide is related to symptom relief during fluticasone treatment in COPD

Lehtimäki

Kankaanranta²,

Saarelainen³

et al. 2009

European Respiratory Journal

View full text Add to dashboard Cite

High levels of exhaled nitric oxide (NO) predict favourable response to inhaled corticosteroids in asthma, but the ability of exhaled NO or inflammatory markers in exhaled breath condensate (EBC) to predict steroid responsiveness in chronic obstructive pulmonary disease (COPD) is not known.We measured alveolar and bronchial NO output, levels of leukotriene B 4 (LTB 4 ), cysteinyl leukotrienes (cysLTs) and 8-isoprostane in EBC, spirometry, body plethysmography and symptoms in 40 subjects with COPD before and after 4 weeks of treatment with inhaled fluticasone (500 mg b.i.d.).Five subjects (12.5%) with COPD had significant improvement in lung function during fluticasone treatment, whereas 20 subjects (50%) had significant decrease in symptoms. High baseline bronchial NO flux was associated with higher increase in forced expiratory volume in 1 s to forced vital capacity ratio (r50.334, p50.038) and more symptom relief (r5 -0.317, p50.049) during the treatment. Baseline EBC levels of LTB 4 , cysLTs or 8-isoprostane were not related to response to fluticasone treatment. Inhaled fluticasone decreased bronchial NO flux but not alveolar NO concentration or markers in EBC.High levels of bronchial NO flux are related to symptom relief and improvement of airway obstruction during treatment with inhaled fluticasone in COPD. Markers of inflammation or oxidative stress in EBC are not related to steroid responsiveness in COPD.

show abstract

Exhaled leukotrienes and prostaglandins in asthma

Cited by 206 publications

References 24 publications

Outcomes for COPD pharmacological trials: from lung function to biomarkers

Outcomes for COPD pharmacological trials: from lung function to biomarkers

Exhaled breath condensate: a comprehensive update

Bronchial nitric oxide is related to symptom relief during fluticasone treatment in COPD

Contact Info

Product

Resources

About